Addition of rituximab to TBI/CY improves the outcome of first-line autologous stem cell transplantation for mantle cell lymphoma

被引：0
|
作者：
Seyfarth, B
Boehme, V
Stuhlmann, R
Sonnen, R
Kneba, M
Schmitz, N
Dreger, P
机构：
[1] Allgemein Krankenhaus St Georg, Hamburg, Germany
[2] Univ Schleswig Holstein, Kiel, Germany
来源：
BONE MARROW TRANSPLANTATION | 2004年 / 33卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S6 / S6
页数：1
相关论文
共 50 条
  • [21] Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
    Le Gouill, S.
    Thieblemont, C.
    Oberic, L.
    Moreau, A.
    Bouabdallah, K.
    Dartigeas, C.
    Damaj, G.
    Gastinne, T.
    Ribrag, V.
    Feugier, P.
    Casasnovas, O.
    Zerazhi, H.
    Haioun, C.
    Maisonneuve, H.
    Houot, R.
    Jardin, F.
    Van den Neste, E.
    Tournilhac, O.
    Le Du, K.
    Morschhauser, F.
    Cartron, G.
    Fornecker, L. -M.
    Canioni, D.
    Callanan, M.
    Bene, M. C.
    Salles, G.
    Tilly, H.
    Lamy, T.
    Gressin, R.
    Hermine, O.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (13): : 1250 - 1260
  • [22] Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma
    Hoster, Eva
    Metzner, Bernd
    Forstpointner, Roswitha
    Pfreundschuh, Michael
    Truemper, Lorenz
    Hallek, Michael
    Woermann, Bernhard
    Duehrsen, Ulrich
    Gisselbrecht, Christian
    Kluin-Nelemans, Hanneke C.
    Van Hoof, Achiel
    Unterhalt, Michael
    Hiddemann, Wolfgang
    Dreyling, Martin H.
    BLOOD, 2009, 114 (22) : 362 - 363
  • [23] First-line therapy, autologous stem-cell transplantation, and post-transplantation maintenance in the management of newly diagnosed mantle cell lymphoma
    Bhella, S.
    Varela, N. P.
    Aw, A.
    Bredeson, C.
    Cheung, M.
    Crump, M.
    Fraser, G.
    Sajkowski, S.
    Kouroukis, T.
    CURRENT ONCOLOGY, 2020, 27 (06) : E632 - E644
  • [24] Mantle cell lymphoma: Promising results with upfront stem cell transplantation using the rituximab/TBI/CY high-dose regimen.
    Seyfarth, B
    Sonnen, R
    Zeis, M
    Pott, C
    Kneba, M
    Schmitz, N
    Dreger, P
    BLOOD, 2001, 98 (11) : 679A - 679A
  • [25] Late Effects after Treatment in Mantle Cell Lymphoma: No Difference By Intensity of First-Line Regimens with or without Autologous Stem Cell Transplantation
    Ekberg, Sara
    Smedby, Karin E.
    Albertsson-Lindblad, Alexandra
    Jerkeman, Mats
    Weibull, Caroline
    Glimelius, Ingrid
    BLOOD, 2021, 138
  • [26] Effectiveness of high-dose cytarabine in first-line treatment of patients with mantle cell lymphoma before autologous stem cell transplantation
    Gruchet, Cecile
    Cayssials, Emilie
    Leleu, Xavier
    Guidez, Stephanie
    HEMATOLOGIE, 2016, 22 (05): : 313 - +
  • [27] Rituximab: enhancing stem cell transplantation in mantle cell lymphoma
    AM Gianni
    S Cortelazzo
    M Magni
    M Martelli
    Bone Marrow Transplantation, 2002, 29 : S10 - S13
  • [28] Rituximab: enhancing stem cell transplantation in mantle cell lymphoma
    Gianni, AM
    Cortelazzo, S
    Magni, M
    Martelli, M
    BONE MARROW TRANSPLANTATION, 2002, 29 (Suppl 1) : S10 - S13
  • [29] Patterns and Outcome of Relapse After Autologous Stem Cell Transplantation for Mantle Cell Lymphoma
    Dietrich, Sascha
    Tielesch, Blanca
    Rieger, Michael
    Nickelsen, Maike
    Pott, Christiane
    Witzens-Harig, Mathias
    Kneba, Michael
    Schmitz, Norbert
    Ho, Antony D.
    Dreger, Peter
    CANCER, 2011, 117 (09) : 1901 - 1910
  • [30] Characteristics and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma
    Dietrich, S.
    Tielesch, B.
    Rieger, M.
    Nickelsen, M.
    Pott, C.
    Witzens-Harig, M.
    Kneba, M.
    Schmitz, N.
    Ho, A.
    Dreger, P.
    ONKOLOGIE, 2010, 33 : 133 - 133
12345